Home -> Answers -> Health & Injury-> Pfizer
Bextra Product RecallOn Apr-07-05 the FDA asked Pfizer, the manufacturer of Bextra, to recall the pain medication from shelves across the U.S. due to risks of heart attacks and strokes in patients. Canada Health quickly followed suit and asked Pfizer to recall Bextra from Canadian shelves. Pfizer has also suspended sales of Bextra in the European Union.
Bextra has been prescribed to arthritis sufferers to relieve symptoms of osteoarthritis and rheumatoid arthritis. Bextra has also been prescribed to women in hopes of relieving PMS and painful menstrual cycles. Bextra is classified as a Cox-2 inhibitor, a newly developed drug in the Non-Steroidal Anti-Inflammatory (NSAID) family. To date, several Cox-2 inhibitors have been banned due to the increased risk of stroke, heart attack, stomach ulcers, liver damage, and severe skin reactions among patients.
On Jan-29-05, health care giant Kaiser Permanente, an HMO serving 2.6 million Californians, stopped prescribing Bextra to its patients.
"This is not a drug that saves lives,'' said Dr. Sharon Levine, a pediatrician who oversees medication usage for Kaiser Permanente's Northern California division. "It's a drug that provides a modest degree of pain relief -- no better than Motrin -- and the size of the risk, given the benefit provided, did not seem warranted.''
On Dec-10-04 the FDA increased the warning on Bextra labels to include a "black box" warning against using the medication for patients with cardiac problems.
On Nov-11-04, University of Pennsylvania researchers told the American Heart Association that a recent clinical trial revealed that patients taking Bextra had more than twice the incidence of heart attack and stroke than nonusers.
On Oct-18-04, Pfizer admitted that two small clinical trials showed heart bypass surgery patients taking Bextra had a higher risk of stroke and heart attack.
University of Pennsylvania pharmacologist Dr. Garret FitzGerald claims "The magnitude of [cardiac problems] with Bextra is even higher than what we saw in Vioxx." Bextra's risk appeared to pose a slightly higher risk than Vioxx for heart attack and stroke. FitzGerald believes that the same mechanism that makes the Cox-2 inhibitor drugs easier on the stomach also blocks a substance that prevents heart problems.
Bextra NewsBextra lawsuit filed in U.S. District court - East St. Louis on behalf of seven plaintiffs; five plaintiffs allegedly suffered strokes and heart attacks after taking the prescription pain reliever and two plaintiffs are filing complaints after their family member died due to cardiovascular problems allegedly associated with Bextra. The lawsuit seeks damages against Pfizer, Pharmacia, Monsanto and Searle with claims that the companies did not disclose proper warnings regarding Bextra's side effects and failed to adequately test Bextra prior to distribution. Monsanto and Searle merged with Pharmacia in 2000 and Pfizer and Pharmacia merged in 2003. (Oct-05-05)
Pfizer tried to pass an injectable pain medication similar to Bextra but the FDA disapproved the drug. Bextra was removed from the market last year after it was linked to the deadly skin disease Stevens-Johnson Syndrome. (Sep-20-05)
The FDA pulls Bextra off the market and issues a Public Health Advisory to patients using Cox-2 inhibitors Bextra and Celebrex warning of side effects and risks of cardiovascular (CV) events and gastrointestinal (GI) bleeding. (Apr-07-05)
Register your Bextra Complaint and Find a Bextra LawyerIf you or a loved one has suffered from the side effects of Bextra, you may qualify for damages or remedies that may be awarded in a possible lawsuit. Find a Bextra Lawyer. Please click the link below to submit your complaint or call 1-866-886-5529 toll free. Click here to submit your complaint through a secure form to United Employees Law Group, PC. Posted on Nov-6-03
Search Blog Directory: